Cross-Sector entity
Genmab is most often covered alongside AbbVie, which appears in 4 of these 4 stories. Across a 22-day span, the pace is roughly 1.3 stories per week. The busiest single day carried 2. The clearest coverage concentration is clinical-trial: 2 of 4 stories, with the rest divided among 2 other categories.
4 verified stories tracked
Last mentioned: Aug 1, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Genmab is most often covered alongside AbbVie, which appears in 4 of these 4 stories. Across a 22-day span, the pace is roughly 1.3 stories per week. The busiest single day carried 2. The clearest coverage concentration is clinical-trial: 2 of 4 stories, with the rest divided among 2 other categories. This profile follows 4 Cross-Sector stories mentioning Genmab across the period from July 11, 2026 to August 1, 2026. The tracked stories average 2.5 original sources each.
Computed from the 4 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Genmab. Shared-story counts are live from our verified record — not editorial picks.
Clarification on US Primary Endpoint
Companies publicly disclosed the trial missed the US primary endpoint of overall survival.
EHA 2026 Presentation
Additional study results presented at the European Hematology Association Congress.
Topline Results Announced
Genmab and AbbVie released initial data from the Phase 3 EPCORE DLBCL-1 trial.
For healthcare providers treating relapsed/refractory DLBCL, the failure of epcoritamab to improve overall survival in a Phase 3 confirmatory trial raises critical questions about its long-term benefit over chemoimmunotherapy, even though the drug is already available under accelerated approval.
The Phase 3 EPCORE DLBCL-1 trial of epcoritamab failed its US overall survival endpoint, jeopardizing full approval and the drug's growing $300 million annual sales. This clarification deepens the competitive threat from other bispecifics with survival data.
Source: finanznachrichten.de · stockhouse.com
A fixed-duration bispecific antibody plus lenalidomide dramatically improved progression-free survival over standard salvage chemoimmunotherapy in relapsed/refractory DLBCL, potentially offering healthcare systems a more effective and less toxic outpatient option while reshaping treatment guidelines and resource utilization.
AbbVie and Genmab's bispecific antibody epcoritamab combined with lenalidomide delivered a hazard ratio of 0.40 in a pivotal DLBCL trial, setting the stage for regulatory filings and a potential second-line market expansion that could challenge CAR-T dominance and redefine the bispecific landscape.
Source: finanznachrichten.de · prnewswire.com
